You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The deal is an extension of an existing agreement involving the license of 14 patents to develop a platform for detecting traumatic brain injury.
LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
Saladax will have the patent rights to Janssen Pharmaceutica's tests that determine drug levels in patients undergoing treatment with antipsychotic drugs.
Beckman said that its assay completes the reproductive menu for its Access immunoassay systems and provides better operational efficiency for labs.
Since purchasing the bioscience unit of Sequenom four years ago, Agena has followed global growth by pushing into more clinical labs in China, as well as Europe.
The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.
Pro-Lab will shepherd Medicortex's kit through the regulatory processes in Canada and the UK, as well as clinically validate it. It will have exclusive rights to sell the kit in the two nations.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
Microdrop will license the rights to market SQI's celiac and wheat allergy, and arthritis tests direct to consumers.
CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.